Mironid, a Glasgow‑based biopharmaceutical firm, closed a €39.9 million ($46 million) Series B financing round on 5 August 2026. The funding is earmarked for clinical development of its small‑molecule therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Mironid announced the completion of the Series B round on 7 August 2026, confirming that the €39.9 million injection will support pre‑clinical and early‑stage clinical studies for its ADPKD candidate. The company is headquartered in Glasgow, Scotland, and the financing involved investors from Europe and North America, including a direct equity contribution from the Scottish National Investment Bank (SNIB).

The financing round was led by existing backers Roche Venture Fund, Epidarex Capital, Sofinnova Partners, and BioGeneration Ventures, with SNIB adding an £8.4 million equity stake. Neil Wilkie, chief executive of Mironid, and Peter Silver and Paul Callaghan of SNIB were identified as primary spokespersons for the transaction. The capital structure of the round combined equity and convertible instruments, enabling Mironid to extend its pipeline activities without diluting founder control.

Funding Structure and Investor Participation

The Series B round raised a total of €39.9 million, equivalent to approximately $46 million at prevailing exchange rates. Of this amount, £34 million was reported in sterling terms, reflecting the inclusion of the £8.4 million SNIB equity investment. Roche Venture Fund, a corporate venture arm of Roche Holding AG, contributed a significant portion of the non‑SNIB capital, reinforcing its strategic interest in renal therapeutics.

The financing round was led by existing backers Roche Venture Fund, Epidarex Capital, Sofinnova Partners, and BioGeneration Ventures, with SNIB adding an £8.4 million equity stake.

Epidarex Capital, a London‑based life‑science fund, and Sofinnova Partners, a European venture capital firm, each provided capital commitments that were disclosed in the press release but not broken down by amount. BioGeneration Ventures, a U.S. early‑stage biotech investor, also participated, completing the investor consortium. The round was structured as a traditional equity financing, with SNIB’s contribution classified as an equity investment rather than a loan, aligning with its mandate to support Scottish innovation.

Clinical Development Roadmap for ADPKD

You may also like

News

Boeing 737 Max Inspections Ordered for Fuselage Cracks

The FAA has mandated inspections of Boeing 737 Max fuselages for potential cracks, affecting 471 aircraft. This directive underscores ongoing safety concerns and may disrupt…

Read More →

Mironid’s lead candidate is a small‑molecule inhibitor designed to slow cyst growth in patients with ADPKD, a genetic disorder affecting approximately 1 in 1,000 individuals worldwide. The Series B proceeds are allocated to complete pre‑clinical toxicology, file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration, and initiate a Phase 1/2 clinical trial in Europe and North America.

The company’s internal timeline projects IND filing by Q4 2026, followed by patient enrollment in the first clinical cohort by early 2027. The funding also supports expansion of the manufacturing platform for the oral formulation, as well as regulatory consulting and data‑management infrastructure. Mironid indicated that the financial runway provided by the Series B round extends operational capacity through at least 2029, assuming successful progression through early clinical milestones.

Implications for Patients and the Biotech Sector

The infusion of €39.9 million positions Mironid to address an unmet therapeutic need in ADPKD, where current treatment options are limited to blood‑pressure control and symptomatic management. If the clinical program meets its endpoints, the therapy could become one of the first disease‑modifying agents for ADPKD, potentially reducing the need for dialysis or transplantation in affected patients.

For the broader biotech ecosystem, the participation of SNIB underscores the Scottish government’s commitment to nurturing high‑growth life‑science companies. The involvement of multinational investors such as Roche Venture Fund signals confidence in the commercial viability of renal‑focused small molecules. The financing round also reflects a trend of mid‑stage European biotech firms securing multi‑hundred‑million‑dollar capital to advance niche therapeutic programs.

Mironid indicated that the financial runway provided by the Series B round extends operational capacity through at least 2029, assuming successful progression through early clinical milestones.

Impact on Readers

Students and educators in biomedical fields can reference Mironid’s financing as a case study of venture‑capital pathways for early‑stage drug development. Researchers focusing on renal genetics may anticipate new data from Mironid’s upcoming trials, informing academic collaborations. Patients and families affected by ADPKD receive a concrete indication that pipeline therapies are advancing toward clinical evaluation, offering a timeline for potential treatment access. Institutional investors and policymakers can observe the funding model as evidence of effective public‑private partnership mechanisms in the UK biotech sector.

Key Facts

• What: Mironid closed a €39.9 million Series B round to fund clinical development of its ADPKD therapy.
• When: Financing closed 5 August 2026; announcement made 7 August 2026.
• Impact: Provides capital to advance a disease‑modifying treatment for a rare kidney disorder and demonstrates continued investment in Scottish biotech.

Sources

You may also like

News

For‑Profit Online Colleges Face Scrutiny Over High Dropout Rates and Student Debt

2026 investigations show for‑profit online colleges have graduation rates below 20 % and average student debt over $30,000, prompting regulatory scrutiny.

Read More →

• Glasgow‑based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment – EU‑Startups
• Biopharma firm Mironid raises fund for kidney treatment – Daily Business Group
• Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease – Mironid Press Release
• Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease – Yahoo Finance